The multikinase inhibitor cabozantinib (Cabometyx) demonstrated a strong intracranial response rate in patients with metastatic renal cell carcinoma (RCC) and brain metastases, according to findings from a retrospective analysis published in JAMA Oncology.1,2
At a median follow-up of 17 months (range, 2-74 months), the intracranial response rate was 55% in a cohort of patients with RCC and progressing brain metastases without concomitant brain-directed local therapy. In a separate cohort of patients with RCC and stable or progressing brain metastases concomitantly treated by brain-directed local therapy, the intracranial response rate was 47%.
“In this cohort study, cabozantinib showed considerable intracranial activity and an acceptable safety profile in patients with RCC and brain metastases. Support of prospective studies evaluating the efficacy of cabozantinib for brain metastases in patients with RCC is critical,” the authors wrote in their study conclusion.
Overall, the retrospective cohort study included 88 patients with metastatic RCC and brain metastases who received single-agent cabozantinib during any line of treatment. Patient had been treated between January 2014 and October 2020 at 15 clinical sites in the United States, Belgium, France, and Spain.
Study cohort A included 33 (38%) patients without concomitant brain-directed local therapy and cohort B included 55 (62%) patients with stable or progressing brain metastases concomitantly treated by brain-directed local therapy. Over three-fourths (78%) of patients were male, and the median age at the start of cabozantinib treatment was 61 years (range, 34-81).
Cohort A had an intracranial response rate of 55% and extracranial response rate of 48%. The median time to treatment failure was 8.9 months and the median overall survival (OS) was 15 months. For cohort B, the intracranial and extracranial response rates were 47% and 38%, respectively. The median time to treatment failure was 9.7 months and the median OS was 16 months.
“We measured the dimension of the metastases in the brain and saw a response rate that was higher than what we usually expect, and there were some nice examples of metastases really shrinking,” senior study author Toni Choueiri, MD, director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, stated in a news release. The news release also noted, however, that Choueiri cautioned that not all of the responses were durable, with some tumors becoming resistant several months later.
Regarding safety, the investigators considered cabozantinib to be well tolerated. There were no unexpected safety signals or neurological adverse events observed. There were also no treatment-related deaths.
To validate these retrospective findings, the ongoing, prospective, multicenter, phase 2 CABRAMETtrial (NCT03967522) is evaluating the safety and efficacy of cabozantinib in patients with metastatic RCC who have brain metastases.
“Hopefully this will be definitive,” Choueiri stated in the release.
Cabozantinib was approved by the FDA in December 2017 as a treatment for previously untreated patients with advanced RCC. Most recently, in January 2021, the FDA approved the combination of nivolumab (Opdivo) plus cabozantinib for the frontline treatment of patients with advanced RCC.
References
1. Targeted drug shows activity against brain metastases in kidney cancer. Published online October 21, 2021. Accessed November 2, 2021. https://bit.ly/3CEIYhT.
2. Hirsch L, Martinez Chanza N, Farah S, et al. Clinical activity and safety of cabozantinib for brain metastases in patients with renal cell carcinoma [published online ahead of print October 21, 2021]. JAMA Oncol. doi: 10.1001/jamaoncol.2021.4544
Dosing commences in phase 1/2 trial of AB-2100 in ccRCC
May 15th 2024The dose escalation/dose expansion study is evaluating the safety and efficacy of AB-2100 in patients with ccRCC who either came back or did not improve following prior treatment with a checkpoint inhibitor and a VEGF inhibitor.
Grant awarded to aid development of allogeneic CAR T treatment for RCC
April 29th 2024“This clinical study has the potential to demonstrate the value of Chimeric Antigen Receptor (CAR) T cell therapy in solid cancers such as kidney cancer with a high unmet medical need,” said Abla Creasey, PhD.
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.
Toripalimab plus axitinib approved in China for renal cell carcinoma
April 11th 2024The approval is based on findings from the phase 3 RENOTORCH trial, which showed that toripalimab plus axitinib prolonged progression-free survival and improved the objective response rate in patients with advanced RCC compared with sunitinib.